Precipio, Inc.
NCM: PRPOLive Quote
About Precipio, Inc.
Healthcare
Diagnostics & Research
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
📊 Fundamental Analysis
Precipio, Inc. demonstrates a profit margin of -1.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 22.9% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -2.7%, which indicates that capital utilization is currently under pressure.
At a current price of $27.25, PRPO currently trades near the top of its 52-week range (91%) (Range: $5.09 - $29.53).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$41.68M
Trailing P/E
--
Forward P/E
69.87
Beta (5Y)
1.20
52W High
$29.53
52W Low
$5.09
Avg Volume
22K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App